Literature DB >> 19932217

Hepatitis B vaccination strategies tailored to different endemicity levels: some considerations.

N Y Rots1, A J Wijmenga-Monsuur, W Luytjes, P Kaaijk, T W de Graaf, B A M van der Zeijst, C J P Boog.   

Abstract

Hepatitis B is a serious public health problem. Worldwide three different levels of hepatitis B endemicity (high, intermediate and low) can be distinguished. Areas with different levels of endemicity require tailored vaccination strategies to fit the needs for individuals at risk and/or countries, depending on the infection risk per age group, vaccination rate, duration of protection after vaccination, cost effectiveness of vaccination strategies and ease of implementation in the national immunization schedules.This opinion paper evaluates these factors and proposes a combination of infant risk group and universal adolescent vaccination for low endemic countries thus targeting the different groups at risk. A universal infant vaccination schedule starting with a newborn vaccination within 24h after birth is more appropriate in intermediate- and high-endemic regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932217     DOI: 10.1016/j.vaccine.2009.10.125

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  The current economic burden of cirrhosis.

Authors:  Guy W Neff; Christopher W Duncan; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10

Review 2.  Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence.

Authors:  Ingrid T Katz; Norma C Ware; Glenda Gray; Jessica E Haberer; Claude A Mellins; David R Bangsberg
Journal:  Sex Health       Date:  2010-09       Impact factor: 2.706

3.  Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment.

Authors:  Solomon Chih-Cheng Chen; Mehlika Toy; Jennifer M Yeh; Jung-Der Wang; Stephen Resch
Journal:  Pediatrics       Date:  2013-03-25       Impact factor: 7.124

4.  Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study.

Authors:  R Bassal; M P Markovich; M Weil; E Shinar; Y Carmeli; M Dan; D Sofer; E Mendelson; D Cohen; T Shohat
Journal:  Epidemiol Infect       Date:  2017-09-14       Impact factor: 4.434

5.  Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.

Authors:  Kathryn L Hopkins; Fatima Laher; Kennedy Otwombe; Gavin Churchyard; Linda-Gail Bekker; Stephen DeRosa; Maphoshane Nchabeleng; Koleka Mlisana; James Kublin; Glenda Gray
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

Review 6.  Hepatitis B vaccination for international travelers to Asia.

Authors:  Kittiyod Poovorawan; Ngamphol Soonthornworasiri; Patiwat Sa-Angchai; Chayasin Mansanguan; Watcharapong Piyaphanee
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-08-17

7.  Characterizing mothers and children at risk of being under-immunized in India: A latent class analysis approach.

Authors:  Taylor A Holroyd; Brian Wahl; Madhu Gupta; Molly Sauer; Madeleine Blunt; Amelia K Gerste; Daniel J Erchick; Mathuram Santosham; Rupali J Limaye
Journal:  Int J Infect Dis       Date:  2020-08-27       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.